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Adenoviral (Ad) vectors are attractive gene delivery vehicles for a number of reasons including, ease of production to high titer, potentially large packaging capacity and systemic stability. 1 However, these vectors have a number of limitations such as induction of inflammatory and immune responses, 2,3 transient gene expression and nonspecific tropism. With regard to this latter point, the recent identification of primary cellular receptors for adenovirus (the coxsackie/adenovirus receptor (CAR) 4, 5 and MHC class I ␣ domain 6 ), is allowing a better understanding of some of the reasons behind this virus's suboptimal transduction efficiency in certain clinical contexts. This is especially the case in certain in vivo applications for both neoplastic 7 and non-neoplastic 8, 9 diseases, where a relative lack of CAR on target cells has been implicated as a limiting factor in successful gene transfer. This inefficient gene transfer compounds the dose-related inflammatory effects of the vector by necessitating the administration of large amounts of the virus, thereby also increasing the risk of nonspecific transduction of non-target organs. To enable both efficient transduction of target cells, and to avoid ectopic transduction of non-target cells, strategies to impart specific targeting properties to the adenovirus have been proposed. In this regard, limited success has been achieved using two broad approaches -the use of bi-specific protein conju-
Correspondence: DT Curiel
Received 24 November 1998; accepted 4 March 1999 gates which simultaneously bind to the virus and to heterologous receptors on the target cells, and the direct genetic modification of the viral particle itself to incorporate a targeting motif. Using the conjugate approach, successful CAR-independent gene transfer has been achieved by targeting viral infection in vitro to several cellular receptors including integrins, 10 folate receptors, 11 basic fibroblast growth factor (FGF2) receptors, 12,13 epidermal growth factor receptors 7, 14 and CD3. 15 Conjugate targeting to FGF2 receptors has also been demonstrated in vivo in a compartmental context in a murine model of ovarian carcinoma. 13 Significantly, this approach has been shown to translate to a therapeutic advantage in comparison to the use of an untargeted vector.
Despite the conceptual gains realized by the conjugate approach, this 'two component' strategy introduces a degree of complexity to the vector system and raises concerns regarding the stability of the virus-conjugate complex under stringent in vivo conditions such as systemic administration. Ultimately therefore, a genetically modified targeted viral particle is a more attractive vector candidate for clinical application. Modified vectors containing short peptide targeting sequences at the C-terminus of the adenoviral knob domain (which binds to CAR) have been produced. By targeting to heparin sulfates 16 or integrins 17 expanded viral tropism has been demonstrated in vitro. These approaches have also resulted in enhanced gene delivery to isolated perfused organs in an ex vivo context, but no effect of these modifications on the transduction distribution profile of the vectors following systemic administration has been achieved. This lack of in vivo data may reflect the disadvantageous position of the C-terminal within the knob domain. Resolution of the crystal structure of the Ad knob domain shows that the C-terminus is located at the base of the knob, facing back toward the viral capsid and thus not in an ideal position to interact efficiently with cellular receptors. 18 In addition, there are very stringent restrictions on the size of ligand that can be added to the C-terminus before these modifications cause failure of trimerization of fiber monomers, 17 which prevents assembly of mature virion particles.
We recently reported the use of an alternate region of the knob domain, the HI loop, as a more rational site for the insertion of targeting motifs. 19 This region does not appear to be directly involved in trimerization, contains mostly hydrophilic amino acids, is of different length in different Ad serotypes, is flexible and is exposed on the exterior of the knob. These attributes suggest this site may be preferable to the C-terminal for motif insertion, both on the basis of accessibility and potentially less rigid structural limitations. Insertion of an Arg-Gly-Asp (RGD) motif in this region resulted in a viral fiber protein which results in efficient CAR-independent infection by allowing binding of Ad to cellular integrins. 20 The vector containing this fiber, Ad5LucRGD, achieved dramatically augmented gene delivery (up to two to three orders of magnitude in comparison with unmodified vector) to several cell types including vascular endothelial cells. Thus, the fidelity of a targeting moiety in this position was maintained and the utility of the HI loop as a propitious locale for the insertion of peptide motifs defined by phage panning technology 21 was established. We recognized, however, that Ad5LucRGD has expanded rather than truly cell-specific tropism, because native binding to CAR has not been ablated. As part of an overall strategy to develop a truly targeted vector, we next sought evidence that insertions into the HI loop would be accessible in the highly stringent context of in vivo systemic administration. No reported genetically tropismmodified vectors have yet demonstrated this capacity. This property is critical if HI loop modifications are to be considered as a rational component of the design of truly cell-specific vectors for clinical use.
To evaluate the systemic gene delivery properties of Ad5LucRGD we compared this virus to a first generation adenovirus vector (AdCMVLuc), which also has a CMVdriven luciferase reporter cassette in E1 but does not have the RGD modification of the fiber protein. Our previous work comparing these two vectors had indicated equivalence of luciferase expression in cells expressing high levels of CAR. 20 Titrating of viral preparations was performed simultaneously by the same operator. Not unexpectedly we did note a difference in plaque forming unit (p.f.u.) to particle ratio, although this was not dramatic (1:60 for Ad5LucRGD and 1:15 for AdCMVLuc). However, any effect of the uninfectious particle component of the viral preparations should have the same impact at each organ site and does not affect the internally normalized distribution profile.
Three separate experiments were performed. Either vector (10 9 p.f.u.) was administered by lateral tail vein injection to C57black6 mice, five mice per group. Three days later the mice were killed and organs (heart, lung, liver, spleen, kidney) were harvested and analyzed for luciferase activity. For each analysis the entire organ was snap-frozen, ground using a mortar and pestle, then cells were lysed in lysis buffer and luciferase activity in the supernatant was measured using a commercial kit (Promega) and a Berthold luminometer. Data were normalized for protein content of the lysates.
Analysis of organ luciferase expression revealed a significant difference in the profile of expression for the two vectors. Higher gene expression was seen for Ad5LucRGD compared with AdCMVLuc in the liver, lung, spleen and kidney, the most striking finding being in the latter instance, where there was consistently greater than 50-fold enhancement of expression. A representative experiment is shown in Figure 1 . Notably, the level of enhancement was different depending on the organ site. Over three experiments mean (± s.d.) liver luciferase expression was 2.6 ± 1.4-fold higher for Ad5LucRGD, whereas kidney expression was 88 ± 32-fold higher and expression in the heart was actually reduced. This pattern cannot be explained by minor differences in the titer of the viral preparations and indicates a different biology for the two vectors.
For both vectors, the highest level of transgene expression was seen in the liver. Uptake of virus in the liver may relate to circulatory factors in combination with both nonspecific and CAR-specific mechanisms. 22 In this regard, there is evidence that the highest levels of mCAR (the murine homologue of human CAR) are found in the mouse liver. 5 Because Ad5LucRGD retains native tropism it is not surprising that hepatic uptake with this vector predominated. Importantly, however, assessment of the ratio of luciferase expression in the other organs to the expression in the liver for each individual mouse again clearly revealed the differential transduction profile of Ad5LucRGD (Figure 2) . Thus, these data provide the first evidence that genetic modification of the adenoviral fiber can lead to altered transgene expression in the highly stringent context of systemic vascular administration.
Several investigators have found that cellular localization of reporter gene expression following systemic administration of adenovirus is difficult in organs other than the liver, due to the predominant sequestration of the vector in this organ. 2 For this reason, in the experiments reported here, we chose to use a luciferase reporter followed by light unit detection. The high sensitivity of this technique enabled reproducible evaluation of the transgene expression profile of the modified vector at the organ level. In an effort to illustrate transgene expression at the cellular level of resolution, we performed in situ hybridization for luciferase mRNA in the various organs. However, owing to limitations of the sensitivity of the technique, we could only detect positive signal in the liver. With both vectors, luciferase mRNA could be detected in hepatocytes. No clear qualitative distinction was seen and although the assay was not performed to provide stringent quantitative data, signal was seen in up to 15% of cells at the dose used (data not shown). Because of the high level of CAR expression in the liver, we believe that further modifications of the vector to reduce hepatic sequestration will be required to allow adequate cellular resolution of non-hepatic transgene expression using currently available techniques.
By far the most likely explanation for our findings is a difference in transduction based upon an interaction between the RGD motif and cellular receptors. However, analysis of transgene expression per se does not in all settings correlate with transduction alone. Transcription and subsequent events could be considered. Based on our previous in vitro work, however, there is no evidence that the fiber modification alters subsequent transcription events. Cells with high levels of CAR, for example 293, which are readily infected by Ad5LucRGD and AdCMVLuc display similar levels of transgene expression when infected with either vector. 20 Our previous work clearly demonstrated that Ad5LucRGD has enhanced binding to cells lacking in CAR and this enhanced binding corresponded to enhanced gene expression. We have also examined a number of cell lines using in situ hybridization for luciferase mRNA and seen greater numbers of transduced cells with Ad5LucRGD than with AdCMVLuc in CAR deficient lines. 23 We have shown that Ad5LucRGD has expanded tropism, but this is not specific. The RGD motif which has been inserted can bind to a number of integrin subtypes, and displays enhanced gene delivery to a variety of cell lines with differing integrin expression profiles. For this reason, attempting to correlate precisely the transgene expression profile with the level of expression for a particular integrin in vivo was not feasible. Such correlations will require the insertion of a much more specific ligand, ideally along with ablation of native tropism. Our data indicate that the HI loop is a rational place for such a ligand.
The data presented in this report address a key issue in the development of targeted adenoviral vectors. Previously, there have been no reports of the properties of targeted vectors administered systemically. In this study, we show that the addition of a RGD motif into the HI loop alters the transgene expression profile of the systemically administered vector, indicating that this region of the vector is an ideal location for the insertion of targeting motifs, and that the attributes of the vector are not undermined by either serum factors or limited motif accessibility. Therefore, this approach, if successfully combined with ablation of native tropism by further modifications, may allow the production of a truly cellspecific vector administerable by the systemic route.
